Market research
SZLS.TO StageZero Life Sciences Ltd
TO CAD Healthcare
Latest close
As of 12 Sep 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1.25
- Dividend yield
- Not available
- Beta
- 0.07
Profile
Instrument facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- CA8525403017
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1.25
- Dividend yield
- Not available
- Beta
- 0.07
About
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Research context
StageZero Life Sciences Ltd appears in PyInvesting’s Toronto Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SZLS.TO discussion.
5 years, 6 months ago
StageZero Life Sciences Ltd is currently in a long term downtrend where the price is trading 45.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.5.
StageZero Life Sciences Ltd's total revenue rose by 2829.8% to $1M since the same quarter in the previous year.
Its net income has dropped by 651.0% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 90.3% to $-40K since the same quarter in the previous year.
Based on the above factors, StageZero Life Sciences Ltd gets an overall score of 3/5.